Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony S Wierzbicki

Showing results (1-10 of 218) with videos related to

Pageof 22
Sort By:
Current Opinion in Lipidology|July 14, 2010
Fibrates: no ACCORD on their use in the treatment of dyslipidaemiaAnthony S Wierzbicki
International Journal of Clinical Practice|September 20, 2006
Low HDL-cholesterol: Common and under-treated, but which drug to use?Anthony S Wierzbicki
Current Opinion in Lipidology|March 14, 2007
Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterolAnthony S Wierzbicki
Diabetes & Vascular Disease Research|July 27, 2007
Homocysteine and cardiovascular disease: a review of the evidenceAnthony S Wierzbicki
Expert Opinion on Investigational Drugs|October 27, 2004
Lipid-lowering therapies in developmentAnthony S Wierzbicki
Current Opinion in Cardiology|May 9, 2009
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemiaAnthony S Wierzbicki
Expert Review of Neurotherapeutics|October 9, 2009
Stroke in systemic lupus erythematosusAnthony S Wierzbicki
International Journal of Clinical Practice|June 20, 2007
Newer, lower, better? Lipid drugs and cardiovascular disease--the continuing storyAnthony S Wierzbicki
International Journal of Clinical Practice|June 20, 2007
Raising HDL-C: back to the future?Anthony S Wierzbicki
Current Opinion in Lipidology|August 15, 2017
The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of careAnthony S Wierzbicki
Pageof 22

Showing results (1-10 of 218) with videos related to

Sort By:
Pageof 22
Current Opinion in Lipidology|July 14, 2010
Fibrates: no ACCORD on their use in the treatment of dyslipidaemiaAnthony S Wierzbicki
International Journal of Clinical Practice|September 20, 2006
Low HDL-cholesterol: Common and under-treated, but which drug to use?Anthony S Wierzbicki
Current Opinion in Lipidology|March 14, 2007
Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterolAnthony S Wierzbicki
Diabetes & Vascular Disease Research|July 27, 2007
Homocysteine and cardiovascular disease: a review of the evidenceAnthony S Wierzbicki
Expert Opinion on Investigational Drugs|October 27, 2004
Lipid-lowering therapies in developmentAnthony S Wierzbicki
Current Opinion in Cardiology|May 9, 2009
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemiaAnthony S Wierzbicki
Expert Review of Neurotherapeutics|October 9, 2009
Stroke in systemic lupus erythematosusAnthony S Wierzbicki
International Journal of Clinical Practice|June 20, 2007
Newer, lower, better? Lipid drugs and cardiovascular disease--the continuing storyAnthony S Wierzbicki
International Journal of Clinical Practice|June 20, 2007
Raising HDL-C: back to the future?Anthony S Wierzbicki
Current Opinion in Lipidology|August 15, 2017
The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of careAnthony S Wierzbicki
Pageof 22